

GE Healthcare

Amersham CyTM5-Streptavidin,

1 mg

New improved

Product Specification Sheet

Code: PA45001

Warning

For research use only.

Not recommended or intended for diagnosis of disease in humans or animals. Do not use internally or externally in humans.

Storage

Store refrigerated at 2–8°C in the dark. Under these conditions, the product is stable for at least 6 months.

Expiry

See outer packaging.

Safety warnings and precautions

All chemicals should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.

Specifications

Protein concentration	1.0 mg/vial
Absorbance maximum	649 nm
Emission maximum	670 nm

Purity

This product was prepared from electrophoretically isolated and purified streptavidin from *Streptomyces Avidinii*. A single precipitin arc was observed against anti-streptavidin when assayed by immunoelectrophoresis.

Formulation

This product is supplied as a lyophilized solid in Phosphate-Buffered Saline (0.02 M Potassium Phosphate, 0.15 M NaCl) pH 7.2, containing 1% (w/v) Bovine Serum Albumin and 0.1% (w/v) Sodium Azide. Reconstitute with 1.0 ml of deionized water, dispense into suitable aliquots and freeze. Avoid repeated freeze-thaw cycles.

Applications

Optimal dilutions will depend on the application. Starting dilutions of 1:1000 for microscopy and 1:400 for flow cytometry are recommended.

Legal

GE and GE Monogram are trademarks of General Electric Company

Amersham and Cy are trademarks of GE Healthcare companies

This product or portions thereof is manufactured under licence from Carnegie Mellon University, US Patent Number 5268486.

© 2006 General Electric Company – All rights reserved.

GE Healthcare reserves the right, subject to any regulatory and contractual approval, if required, to make changes in specification and features shown herein, or discontinue the product described at any time without notice or obligation.

Contact your GE Healthcare representative for the most current information and a copy of the terms and conditions.

www.gehealthcare.com/lifesciences

GE Healthcare UK Limited
Amersham Place, Little Chalfont,
Buckinghamshire, HP7 9NA UK

GE Healthcare Bio-Sciences AB
Björkgatan 30 751 84,
Uppsala Sweden

GE Healthcare Europe GmbH
Munzinger Strasse 5 D-79111,
Freiburg Germany

GE Healthcare Bio-Sciences Corp
800 Centennial Avenue PO Box 1327,
Piscataway NJ 08855-1327 USA

GE Healthcare Bio-Sciences KK
Sanken Bldg 3-25-1, Hyakunincho Shinjuku-ku,
Tokyo 169-0073 Japan

